Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05110781 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
A Phase 2 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05110781 is a Phase 2 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 1 participants.
The verdict
NCT05110781, a Phase 2 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial tests whether atezolizumab works to shrink tumors before surgery in patients with head and neck squamous cell cancer with an unknown or historic primary site that has spread to other places in the lymph nodes (regionally metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab before surgery may reduce the size of the tumor.
Interventions
- BIOLOGICAL Atezolizumab
- RADIATION Radiation Therapy
- PROCEDURE Therapeutic Conventional Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2023-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05110781
The ClinicalTrials.gov registry entry for NCT05110781 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT05110781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05110781 about?
NCT05110781 is a clinical study titled "Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site". This phase II trial tests whether atezolizumab works to shrink tumors before surgery in patients with head and neck squamous cell cancer with an unknown or historic primary site that has spread to other places in the lymph nodes (regionally metastatic). Immunotherapy with monoclonal antibodies, such...
What is the current status of trial NCT05110781?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-12-07. Estimated completion is 2023-04-18.
What interventions are being tested in trial NCT05110781?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Radiation Therapy (RADIATION), Therapeutic Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT05110781?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.